Dare Bioscience (DARE) Cash from Financing Activities (2013 - 2025)
Dare Bioscience's (DARE) quarterly Cash from Financing Activities came in at $424129.0 in Q4 2025, up 300.7% YoY from $105845.8 in Q4 2024, and down 97.73% on a QoQ basis from $18.7 million in Q3 2025.
Dare Bioscience (DARE) Cash from Financing Activities (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Cash from Financing Activities data on file, last reported at $424129.0 in Q4 2025.
- Quarterly Cash from Financing Activities rose 300.7% year-over-year to $424129.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.3 million (up 5337.5% YoY) and the FY2025 annual result came in at $19.3 million, up 5337.5% from the prior year.
- Cash from Financing Activities fell to $424129.0 in Q4 2025, from $18.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $35.2 million in Q3 2021 to a low of -$211320.0 in Q4 2024.
- A 5-year average of $5.9 million and a median of $452195.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 530926900.0% — and 2025, when it plunged 137.96%.
- Tracing DARE's Cash from Financing Activities over 5 years: stood at $16.0 million in 2021, then sank by 100.0% to -$1.0 in 2022, then jumped by 530926900.0% to $5.3 million in 2023, then tumbled by 103.98% to -$211320.0 in 2024, then soared by 300.7% to $424129.0 in 2025.
- The last three Cash from Financing Activities figures came in at $424129.0 (Q4 2025), $18.7 million (Q3 2025), and -$43794.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 424,129.00 |
| Dec 31, 2025 | 424,129.00 |
| Sep 30, 2025 | 18.65 Mn |
| Sep 30, 2025 | 18.65 Mn |
| Jun 30, 2025 | -43,794.00 |
| Jun 30, 2025 | -43,794.00 |
| Mar 31, 2025 | 246,577.00 |
| Mar 31, 2025 | 246,577.00 |
| Dec 31, 2024 | -211,320.00 |
| Dec 31, 2024 | -211,320.00 |
| Sep 30, 2024 | 436,444.00 |
| Sep 30, 2024 | 436,444.00 |
| Jun 30, 2024 | 115,366.00 |
| Jun 30, 2024 | 115,366.00 |
| Mar 31, 2024 | 14,032.00 |
| Mar 31, 2024 | 14,032.00 |
| Dec 31, 2023 | 5.31 Mn |
| Dec 31, 2023 | 5.31 Mn |
| Sep 30, 2023 | 8.58 Mn |
| Sep 30, 2023 | 8.58 Mn |